Dr. Pierre Leblond works at the Léon Bérard Comprehensive Cancer Center (Lyon, France) and previously at the Oscar Lambret Cancer Center (Lille, France). After completing his first medical degrees in Paris and in Lille, and two fellowships in pediatrics and pediatric hematology and oncology, he joined the pediatric oncology team at the Oscar Lambret Center in Lille as a senior pediatric oncologist, and was in charge of children with brain tumors and responsible for early phase clinical trials. Since 2018, he has joined the Institut d’Hématologie et d’Oncologie Pédiatrique (IHOPe) team in Lyon, where he provides care for children and adolescents with brain tumors, as well as the management of the pediatric clinical trials office. He is the coordinator of early phase clinical trials and the coordinator of the European SIOP Ependymoma II program. He was the coordinator of the new drugs and of the brain tumors committees of the French society for children with cancer as well as a member of the clinical trial committee of the European ITCC consortium. In 2013, he obtained a PhD in cellular and molecular biology, the subject of which focused on the preclinical evaluation of new drugs in neuroblastoma and high-grade glioma models. Dr. Leblond is part of a research team (basic science) dedicated to exploring the resistance to treatment of pediatric tumors (Dr Castets, Pr Blay). He participates in generating tumoroids, with a particular focus on high-grade gliomas/DIPG and ependymoma.